CSTL

Castle Biosciences' stock has experienced significant volatility, with a 52-week range between $14.59 and $44.28. In Q1 2026, the company reported strong results with revenue of $83.7 million, exceeding forecasts, and increased its full-year revenue guidance, but reported a net loss of $14.5 million. New data presented at the 2026 American Academy of Dermatology Annual Meeting demonstrated that DecisionDx-Melanoma refines mortality risk, and data from Mayo Clinic showed that TissueCypher improves risk stratification for Barrett's esophagus. The company held its Q4 2025 earnings call and released preliminary results, influencing stock performance. A Novitas Local Coverage Determination (LCD) that included DecisionDx-SCC as noncovered impacted test report volume for the nine months ended September 30, 2025.